Creative Medical Technology Holdings announced positive data and filing of a patent application covering the use of ImmCelz® in prevention and regression of type 1 diabetes.
Creative Medical Technology Holdings announced positive preclinical data supporting the utilization of its ImmCelz® cell-based immunotherapy for treatment of stroke.